PURE Bioscience Announces Licensing and Distribution Agreement with Brazilian Distributors for SDC Antibacterial Product
SAN DIEGO, CA March 1, 2007—PURE Bioscience (OTCBB: PURE) today announced it has granted a license to market and its sell silver dihydrogen citrate (SDC)-based products in Brazil to privately held Life Biociencias S/A of Apucarana, Parana in Brazil (Lifebio) together in a joint venture with privately held PCI International, Inc. of Lafayette, Louisiana (PCI).
Under the terms of the Supply, Distribution and License Agreement, PURE will sell concentrate to Lifebio/PCI for blending, packaging, and distribution of non-pharmaceutical SDC-based antimicrobial products. Lifebio/PCI will actively market products based upon or containing PURE’s SDC antimicrobial for use in household, institutional, industrial, agricultural and food processing products and applications. In addition, Lifebio/PCI will assume compliance responsibility for all regulatory and legal requirements by Brazilian national, state and local governments. Specific financial terms of the multi-year contract were not disclosed.
L. Felippe C. De Castro, President and CEO of PCI stated, “We are extremely excited about this new venture with PURE Bioscience, and we strongly believe SDC will replace many toxic chemicals in multiple markets. SDC sets a new benchmark for efficacy and safety, and we think it will be the standard for many years to come.”
Lifebio is one member of the Grupo Sacchelli conglomerate. Several other companies owned by Grupo Sacchelli intend to incorporate SDC into their processes and/or products.
Dr. Nilson Umberto Sacchelli Ribeiro, a Director of Grupo Sacchelli, added, “We have established joint development programs with Ministries of Health and Agriculture to conduct research and develop SDC-based products for use in healthcare as well as for use in farming and ranching and in food processing, packaging and distribution.”
Ribeiro continued, “Our early marketing efforts for SDC-based disinfectant target federal, state and municipal governments, hospitals, doctors’ offices and clinics and other institutional users. We also plan to immediately present the technology to the food industry as a superior food contact antimicrobial and preservative. Additionally, we are currently exploring the use of SDC as an antimicrobial in cooling towers. Marketing across the country of
Michael L. Krall, President and CEO of PURE Bioscience, commented, “Given the accelerating adoption of SDC technology in US applications, we are very excited about international interest in SDC.
About PCI International, Inc.
PCI International, Inc. was established in 1981 as an international consulting, trading and government relations firm, with highly specialized expertise in international trade and economic development. PCI is always prepared to meet the industry’s changing needs and toughest challenges. PCI was formed to provide substantial counsel in international trade opportunities, to develop International projects and to pursue its clients best interests in any given market and its government, specifically in the country of
About Life Biociencias S/A
Lifebio, established solely to develop and promote silver dihydrogen citrate as a platform technology in
About PURE Bioscience
PURE Bioscience (PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented silver dihydrogen citrate (SDC), is an electrolytically generated source of stabilized ionic silver. SDC destroys bacteria by disabling proteins and halting metabolic and reproductive functions. SDC is colorless, odorless, tasteless, non-caustic and formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. It also offers 24-hour residual protection against standard indicator bacteria. PURE Bioscience, headquartered in
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
# # #